Lexicon Genetics Lands Merck as Licensee | GenomeWeb

NEW YORK, Aug. 15 – Merck has acquired a non-exclusive license to Lexicon Genetics' gene-targeting technologies, bringing to 16 the total number of licensees for the technologies, Lexicon said on Wednesday.

Details of the agreement were not disclosed.

Lexicon Genetics, of The Woodlands, Texas, uses gene-knockout technology to identify genes of medical interest. In addition to licensing this technology, Lexicon uses it to develop its own drug-discovery efforts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.